BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 24375277)

  • 21. Prognostic relevance of stromal CD26 expression in rectal cancer after chemoradiotherapy.
    Saigusa S; Toiyama Y; Tanaka K; Inoue Y; Mori K; Ide S; Imaoka H; Kawamura M; Mohri Y; Kusunoki M
    Int J Clin Oncol; 2016 Apr; 21(2):350-358. PubMed ID: 26370256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunohistochemical detection of high-mobility group box 1 correlates with resistance of preoperative chemoradiotherapy for lower rectal cancer: a retrospective study.
    Hongo K; Kazama S; Tsuno NH; Ishihara S; Sunami E; Kitayama J; Watanabe T
    World J Surg Oncol; 2015 Jan; 13():7. PubMed ID: 25622595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The disparate twins: a comparative study of CXCR4 and CXCR7 in SDF-1α-induced gene expression, invasion and chemosensitivity of colon cancer.
    Heckmann D; Maier P; Laufs S; Li L; Sleeman JP; Trunk MJ; Leupold JH; Wenz F; Zeller WJ; Fruehauf S; Allgayer H
    Clin Cancer Res; 2014 Feb; 20(3):604-16. PubMed ID: 24255072
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression and prognostic value of CXCL12/CXCR4/CXCR7 axis in clear cell renal cell carcinoma.
    Potić Floranović M; Ristić Petrović A; Veličković F; Janković Veličković L
    Clin Exp Nephrol; 2021 Oct; 25(10):1057-1069. PubMed ID: 34109508
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High expression of CXCR4 and CXCR7 predicts poor survival in gallbladder cancer.
    Yao X; Zhou L; Han S; Chen Y
    J Int Med Res; 2011; 39(4):1253-64. PubMed ID: 21986127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rsf-1 expression in rectal cancer: with special emphasis on the independent prognostic value after neoadjuvant chemoradiation.
    Lin CY; Tian YF; Wu LC; Chen LT; Lin LC; Hsing CH; Lee SW; Sheu MJ; Lee HH; Wang YH; Shiue YL; Wu WR; Huang HY; Hsu HP; Li CF; Chen SH
    J Clin Pathol; 2012 Aug; 65(8):687-92. PubMed ID: 22569540
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression pattern of the CXCL12/CXCR4-CXCR7 trio in Kaposi sarcoma skin lesions.
    Desnoyer A; Dupin N; Assoumou L; Carlotti A; Gaudin F; Deback C; Peytavin G; Marcelin AG; Boué F; Balabanian K; Pourcher V;
    Br J Dermatol; 2016 Dec; 175(6):1251-1262. PubMed ID: 27177037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The expression of CXCR4, CXCL12 and CXCR7 in malignant pleural mesothelioma.
    Li T; Li H; Wang Y; Harvard C; Tan JL; Au A; Xu Z; Jablons DM; You L
    J Pathol; 2011 Mar; 223(4):519-30. PubMed ID: 21294125
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elevated platelet count is a negative predictive and prognostic marker in locally advanced rectal cancer undergoing neoadjuvant chemoradiation: a retrospective multi-institutional study on 965 patients.
    Belluco C; Forlin M; Delrio P; Rega D; Degiuli M; Sofia S; Olivieri M; Pucciarelli S; Zuin M; De Manzoni G; Di Leo A; Scabini S; Zorcolo L; Restivo A
    BMC Cancer; 2018 Nov; 18(1):1094. PubMed ID: 30419864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proinflammatory CXCL12-CXCR4/CXCR7 Signaling Axis Drives Myc-Induced Prostate Cancer in Obese Mice.
    Saha A; Ahn S; Blando J; Su F; Kolonin MG; DiGiovanni J
    Cancer Res; 2017 Sep; 77(18):5158-5168. PubMed ID: 28687617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Profiling of Cxcl12 receptors, Cxcr4 and Cxcr7 in murine testis development and a spermatogenic depletion model indicates a role for Cxcr7 in controlling Cxcl12 activity.
    Westernströer B; Terwort N; Ehmcke J; Wistuba J; Schlatt S; Neuhaus N
    PLoS One; 2014; 9(12):e112598. PubMed ID: 25460567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression.
    Sun X; Cheng G; Hao M; Zheng J; Zhou X; Zhang J; Taichman RS; Pienta KJ; Wang J
    Cancer Metastasis Rev; 2010 Dec; 29(4):709-22. PubMed ID: 20839032
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preoperative chemoradiotherapy improves local recurrence free survival in locally advanced rectal cancer.
    Tural D; Ozturk M; Selcukbiricik F; Yildiz O; Elicin O; Turna H; Guney S; Ozguroglu M
    J BUON; 2013; 18(2):385-90. PubMed ID: 23818350
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of the Chemokine Receptors CXCR4 and CXCR7 on Clinical Outcome in Adrenocortical Carcinoma.
    Chifu I; Heinze B; Fuss CT; Lang K; Kroiss M; Kircher S; Ronchi CL; Altieri B; Schirbel A; Fassnacht M; Hahner S
    Front Endocrinol (Lausanne); 2020; 11():597878. PubMed ID: 33281749
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lymph node metastases in rectal cancer after preoperative radiochemotherapy: impact of intramesorectal distribution and residual micrometastatic involvement.
    Sprenger T; Rothe H; Becker H; Beissbarth T; Homayounfar K; Gauss K; Kitz J; Wolff H; Scheel AH; Ghadimi M; Rödel C; Conradi LC; Liersch T
    Am J Surg Pathol; 2013 Aug; 37(8):1283-9. PubMed ID: 23851331
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic effects of oxaliplatin-based neoadjuvant chemotherapy and chemoradiotherapy in patients with locally advanced rectal cancer: a single-center, retrospective cohort study.
    Okuyama T; Sameshima S; Takeshita E; Yoshioka R; Yamagata Y; Ono Y; Tagaya N; Noie T; Oya M
    World J Surg Oncol; 2018 Jun; 16(1):105. PubMed ID: 29871650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical significance of fibroblast growth factor receptor 2 expression in patients with residual rectal cancer after preoperative chemoradiotherapy: relationship with KRAS or BRAF mutations and MSI status.
    Yoon G; Lee H; Kim JH; Hur K; Seo AN
    Tumour Biol; 2016 Aug; 37(8):10209-18. PubMed ID: 26831663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elevated CD133, but not VEGF or EGFR, as a predictive marker of distant recurrence after preoperative chemoradiotherapy in rectal cancer.
    Yasuda H; Tanaka K; Saigusa S; Toiyama Y; Koike Y; Okugawa Y; Yokoe T; Kawamoto A; Inoue Y; Miki C; Kusunoki M
    Oncol Rep; 2009 Oct; 22(4):709-17. PubMed ID: 19724847
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug Design Targeting the CXCR4/CXCR7/CXCL12 Pathway.
    Xu D; Li R; Wu J; Jiang L; Zhong HA
    Curr Top Med Chem; 2016; 16(13):1441-51. PubMed ID: 26369824
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Common structural interactions between the receptors CXCR3, CXCR4 and CXCR7 complexed with their natural ligands, CXCL11 and CXCL12, by a modeling approach.
    Costantini S; Raucci R; De Vero T; Castello G; Colonna G
    Cytokine; 2013 Oct; 64(1):316-21. PubMed ID: 23773308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.